Therapeutics: An undetermined target

A mouse study suggests the mitochondrial-targeting antioxidant MitoQ could help treat Angelman syndrome. Hippocampal levels of mitochondrial superoxide were higher in a mouse model of Angelman syndrome than in normal mice. In the mouse model, MitoQ decreased mitochondrial superoxide levels in the hippocampus and memory deficits compared with vehicle. Next steps could include testing the effect of MitoQ in other neurological disorders...